Biohaven reports positive degrader data achieving > 80% sustained reductions in total igg with potential first-in-class bhv-1300

Optimized subcutaneous administration of bhv-1300 achieved rapid, deep and sustained lowering of igg, differentiating biohaven's new small molecule class of degraders from the monoclonal antibody fcrn-targeting competition. up to 84% reduction of total igg was observed with a median reduction of 80% after subcutaneous weekly 1000 mg dosing in the ongoing phase 1 study.
BHVN Ratings Summary
BHVN Quant Ranking